MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

NCT00796965 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-08-19

No results posted yet for this study

Summary

Single Ascending Dose Study

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD7268

Solution/Capsule, Oral, once daily

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Sylvan Hurewitz, M.D. · AstraZeneca Clinical Pharmacology Unit, US

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00796965 on ClinicalTrials.gov